Evidence map›Paper›PMID 27752283›Full record

ArticleJournal of biological engineering2016

Design and engineering of a transmissible antiviral defense.

Matthew L Paff, Scott L Nuismer, Andrew D Ellington, Ian J Molineux, Ryan H May, James J Bull

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biological engineering, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Matthew L PaffDepartment of Integrative Biology, University of Texas at Austin, Austin, 78712 TX USA ; Institute of Cellular and Molecular Biology, University of Texas at Austin, Austin, 78712 TX USA.
Scott L NuismerDepartment of Biological Sciences, University of Idaho, Moscow, 83843 ID USA.
Andrew D EllingtonDepartment of Molecular Biosciences, University of Texas at Austin, Austin, 78712 TX USA ; Institute of Cellular and Molecular Biology, University of Texas at Austin, Austin, 78712 TX USA ; Center for Systems and Synthetic Biology, University of Texas at Austin, Austin, 78712 TX USA.
Ian J MolineuxDepartment of Molecular Biosciences, University of Texas at Austin, Austin, 78712 TX USA ; Institute of Cellular and Molecular Biology, University of Texas at Austin, Austin, 78712 TX USA.
Ryan H MayDepartment of Biological Sciences, University of Idaho, Moscow, 83843 ID USA.
James J BullDepartment of Integrative Biology, University of Texas at Austin, Austin, 78712 TX USA ; Institute of Cellular and Molecular Biology, University of Texas at Austin, Austin, 78712 TX USA ; Center for Computational Biology and Bioinformatics, University of Texas at Austin, Austin, 78712 TX USA.

Funding

Experimental viral evolution at high mutation rateR01GM057756 · NIGMS · UNIVERSITY OF TEXAS AUSTIN · PI BULL, JAMES J · 1998 to 2013
$2.9M
NIGMS NIH HHS R01 GM057756
6 · The paper itself

Abstract

backgroundWe propose, model, and implement a novel system of population-level intervention against a virus. One context is a treatment against a chronic infection such as HIV. The underlying principle is a form of virus 'wars' in which a benign, transmissible agent is engineered to protect against infection by and spread of a lethal virus. In our specific case, the protective agent consists of two entities, a benign virus and a gene therapy vector mobilized by the benign virus.

resultsNumerical analysis of a mathematical model identified parameter ranges in which adequate, population-wide protection is achieved. The protective system was implemented and tested using

conclusionsOverall, there is a reasonable marriage between the mathematical model and the empirical system, suggesting that such models can be useful guides to the design of such systems even before the models incorporate most of the relevant biological details.

Indexed as

BacteriophageGenetic engineeringTransmissible vaccineVirus

Identifiers

PMID27752283
PMCPMC5062863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.